Renal Cancer - Results from #1780

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient? November 10, 2021

Thromboembolism in Patients with Metastatic Renal Cell Carcinoma Treated with Immunotherapy. November 9, 2021

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. November 9, 2021

Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21). November 8, 2021

Pilot study of Tremelimumab with and without cryoablation in patients with metastatic renal cell carcinoma. November 8, 2021

Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. November 8, 2021

External Validation of the ASSURE Model for Predicting Oncological Outcomes After Resection of High-risk Renal Cell Carcinoma (RESCUE Study: UroCCR 88). November 5, 2021

Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing. November 4, 2021

Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. November 4, 2021

Emotional state and cancer-related self-efficacy as affecting resilience and quality of life in kidney cancer patients: a cross-sectional study. November 3, 2021

Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. November 3, 2021

Involvement of PBRM1 in VHL disease-associated clear cell renal cell carcinoma and its putative relationship with the HIF pathway. November 2, 2021

Prognostic Value of Metabolism-Related Genes and Immune Infiltration in Clear Cell Renal Cell Carcinoma. November 2, 2021

Impact of frailty on perioperative and oncologic outcomes in patients undergoing surgery or ablation for renal cancer: a systematic review. November 1, 2021

Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. November 1, 2021

Cytoreductive nephrectomy and exposure to sunitinib - a post-hoc analysis of the SURTIME trial. October 29, 2021

The Potential and Limitations of Precision Oncology: Lessons Learned from Whole-Exome Sequencing in an Exceptional Response to Everolimus in Advanced Renal Cell Carcinoma. October 29, 2021

Identification of C3 and FN1 as potential biomarkers associated with progression and prognosis for clear cell renal cell carcinoma. October 28, 2021

Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma. October 28, 2021

Association between prior nephrectomy and efficacy of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma - A systematic review and meta-analysis. October 27, 2021

Page 90 of 456